{"id":10746,"date":"2026-11-04T18:13:09","date_gmt":"2026-11-04T12:43:09","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-11-04\/"},"modified":"2026-11-04T18:13:11","modified_gmt":"2026-11-04T12:43:11","slug":"zyduslife-share-price-today-2026-11-04","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-11-04\/","title":{"rendered":"Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 4.23% | 4 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: ZYDUSLIFE<\/strong> \u00b7 4 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,188.10<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-4.23%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,266.60 \/ \u20b91,182.40<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,240.60<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>49.43 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>4 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Zydus Lifesciences Ltd (ZYDUSLIFE) shares declined sharply by 4.23% today, closing at \u20b91,188.10 after opening at \u20b91,251.70. The stock traded within a wide intraday range, hitting a high of \u20b91,266.60 and a low of \u20b91,182.40.<\/li>\n<li>Zydus Lifesciences announced its unaudited consolidated financial results for the quarter ended September 30, 2026, reporting revenue from operations of \u20b979,096 million, marking a 29% increase over the previous year. EBITDA for the quarter stood at \u20b918,945 million, down 6% year-on-year, while net profit declined 27% year-on-year to \u20b99,255 million. The company reported R&amp;D investments of \u20b96,573 million, accounting for 8.3% of revenues, and organic capex of \u20b94,655 million.<\/li>\n<li>Trading volume was 3.58 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Zydus Lifesciences share price falling on 4 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Zydus Lifesciences Ltd (ZYDUSLIFE) shares declined sharply by 4.23% today, closing at \u20b91,188.10 after opening at \u20b91,251.70. The stock traded within a wide intraday range, hitting a high of \u20b91,266.60 and a low of \u20b91,182.40.<\/p>\n<p class=\"wt-copy\">The broader market and sector moved in the opposite direction, providing an interesting contrast to the stock&#x27;s performance. The benchmark Nifty rose by 0.63%, while the thematic sector index Nifty Pharma advanced by 0.42%. Zydus Lifesciences underperformed both the broader market and its sector peers significantly during the session.<\/p>\n<p class=\"wt-copy\">The move coincided with the release of the company&#x27;s financial results for the quarter ended September 30, 2026, alongside reports of USFDA inspection observations at its Moraiya and Ahmedabad facilities. While the company reported a 29% year-on-year increase in revenue from operations to \u20b979,096 million, net profit for the quarter declined 27% year-on-year to \u20b99,255 million, and EBITDA dropped 6% to \u20b918,945 million.<\/p>\n<p class=\"wt-copy\">49.43 lakh shares traded by 4 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 13.80 lakh shares (3.58 times). The five-day average daily volume was 16.14 lakh shares. Separately, the NSE report for 4 November 2026 showed 17.98 lakh shares delivered, representing 36.38% of that day\u2019s traded volume. The same report recorded 173,344 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>profit-taking following earnings and regulatory updates<\/strong><\/p>\n<p class=\"wt-copy\">The stock declined 4.23% alongside heavy trading volume after reporting a year-on-year drop in quarterly net profit and EBITDA despite higher revenues, alongside disclosed USFDA inspection observations at key manufacturing plants.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2 FY27 Financial Results and Operating Update<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Zydus Lifesciences announced its unaudited consolidated financial results for the quarter ended September 30, 2026, reporting revenue from operations of \u20b979,096 million, marking a 29% increase over the previous year. EBITDA for the quarter stood at \u20b918,945 million, down 6% year-on-year, while net profit declined 27% year-on-year to \u20b99,255 million. The company reported R&amp;D investments of \u20b96,573 million, accounting for 8.3% of revenues, and organic capex of \u20b94,655 million.<\/p>\n<p class=\"wt-copy\">Quarterly earnings figures and margin contraction provide critical visibility into the company&#x27;s operational profitability and growth trajectory.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">USFDA Facility Inspections Update<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company disclosed that USFDA inspections at its SEZ II facility in Ahmedabad and formulations plant in Moraiya concluded with one and five observations, respectively. Zydus stated that it is working closely with the regulator to address these observations expeditiously. Following the inspection at Moraiya, the company also received approval for a transdermal patch product on October 21, 2026.<\/p>\n<p class=\"wt-copy\">Regulatory observations at key manufacturing sites can influence compliance sentiment and future product approval timelines in regulated markets.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Acquisition of Sterling Biotech&#x27;s API Business<\/div>\n<div class=\"wt-card-date\">2 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Upon completion of conditions precedent and closing adjustments under the Business Transfer Agreement dated September 17, 2024, Zydus Lifesciences completed the acquisition of the API business of Sterling Biotech Limited on November 2, 2026. The integration aims to strengthen the company&#x27;s backward integration and manufacturing capabilities. This follows ongoing strategic alignment across its domestic and international manufacturing footprint.<\/p>\n<p class=\"wt-copy\">Expanding API operations enhances backward integration and supply chain control across the pharmaceutical portfolio.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_02112026124012_Zydus_SBL_API_BTA_closing.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Outcome of Board Meeting<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Outcome of Board Meeting held on November 04, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_04112026122736_SEIntimationStatutoryAuditors.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">4 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_04112026121711_OutcomeofBM.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">75.01%<\/div>\n<div class=\"wt-note\">75.01% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">7.05%<\/div>\n<div class=\"wt-note\">6.88% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">18.33%<\/div>\n<div class=\"wt-note\">18.15% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1733872_07102026051035_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Jasodaben Babubhai Patel<\/strong><span class=\"wt-note\">Promoter Group<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>1,000 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>12 November 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 6.88% on 30 September 2026. This compares with 5.12% on 30 June 2026, a change of +1.76 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 41 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Parag Parikh Flexi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.01 crore shares \u00b7 2.01%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Quant Mutual Fund &#8211; Quant Multi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.48 crore shares \u00b7 1.49%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Kotak Flexicap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.07 crore shares \u00b7 1.07%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1733872_07102026051035_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Kotak<\/div>\n<div class=\"wt-card-date\">2 November 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Included Zydus Lifesciences among stock recommendations in its daily notes.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Macquarie<\/div>\n<div class=\"wt-card-date\">27 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Outperform<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained an Outperform rating following business updates.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Citi<\/div>\n<div class=\"wt-card-date\">12 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Sell<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Raised target price while maintaining a Sell rating on valuation concerns.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">20 May 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Neutral<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b91,125.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a Neutral rating citing limited immediate upside potential.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Company management commentary and answers during the post-results earnings call<\/li>\n<li>Regulatory response and resolution progress regarding USFDA observations at Moraiya and Ahmedabad facilities<\/li>\n<li>Execution and integration progress following the acquisition of Sterling Biotech&#x27;s API business<\/li>\n<li>Sustained performance of domestic branded formulations and US specialty product momentum<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-23\/\">Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 0.84% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-22\/\">Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Rising 1.58% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-10-16\/\">Zydus Lifesciences in Focus After Sri Lanka Plant Agreement; What to Watch | 16 October 2026 \u2014 16 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/zyduslife\/\">More Zydus Lifesciences news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Zydus Lifesciences company news?<\/h3>\n<p class=\"wt-copy\">Zydus Lifesciences announced its unaudited consolidated financial results for the quarter ended September 30, 2026, reporting revenue from operations of \u20b979,096 million, marking a 29% increase over the previous year. EBITDA for the quarter stood at \u20b918,945 million, down 6% year-on-year, while net profit declined 27% year-on-year to \u20b99,255 million. The company reported R&amp;D investments of \u20b96,573 million, accounting for 8.3% of revenues, and organic capex of \u20b94,655 million.<\/p>\n<h3>How strong was Zydus Lifesciences\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">49.43 lakh shares traded, 3.58 times the 20-day average daily volume. The price and volume data are dated 4 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-11-04\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/zyduslife-share-price-today-2026-11-04\/\"}, \"headline\": \"Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 4.23% | 4 November 2026\", \"description\": \"Zydus Lifesciences share price fell 4.23% to \u20b91,188.10 today. See why ZYDUSLIFE is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-11-04T18:12:58.487396+05:30\", \"dateModified\": \"2026-11-04T18:12:58.487396+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Zydus Lifesciences\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"ZYDUSLIFE\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/zyduslife-company-news-2026-11-04.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Investor Presentation\",\"summary\":\"Investor Presentation\",\"source\":\"NSE\",\"published\":\"04-Nov-2026 12:35:20\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_04112026123450_Investorpresentation.pdf\",\"disclosure_text\":\"November 4, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai\u2013400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C\/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai\u2013400 051 Re: Investor Presentation Ref.: Disclosure under regulation 30 read with regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cthe Listing Regulations\u201d) Dear Sir, Pursuant to the provisions of regulation 30 read with regulation 46 of the Listing Regulations, please find attached the Investor Presentation on the unaudited financial results for the quarter \/ half year ended on September 30, 2026. Please find the same in order. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Zydus Lifesciences Limited Earnings Presentation: Q2 FY27 4th November 2026 Disclaimer and Safe Harbor Statement \u2022 THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE \u201cCOMPANY\u201d). The material that follows is a Presentation of general background information about the Company\u2019s activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe \/ purchase the Company shares. This Presentation includes statements that are, or may be deemed to be, \u201cforward-looking statements\u201d. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms \u201cbelieves\u201d, \u201cestimates\u201d, \u201canticipates\u201d, \u201cprojects\u201d, \u201cexpects\u201d, \u201cintends\u201d, \u201cmay\u201d, \u201cwill\u201d, \u201cseeks\u201d or \u201cshould\u201d or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company\u2019s intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates. \u2022 By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward- looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company\u2019s actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc. \u2022 The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates. This document is just a Presentation and is not intended to be a \u201cprospectus\u201d or \u201coffer document\u201d or a \u201cprivate placement offer letter\u201d (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company\u2019s equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company\u2019s securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from. This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever. 2 India Formulations 24% North America Formulations 43% API & Others 3% IM Formulations 13% MedTech 3% Consumer Wellness 14% \u2751 USFDA inspections at SEZ II, Ahmedabad and Moraiya formulations facilities concluded with one and five observations, respectively. \u2751 Post inspection at Moraiya site, received approval for a transdermal product on October 21, 2026. \u2751 Total revenues grew 29% YoY. \u2751 Within Pharmaceutical business, \u27a2 India branded formulations sustained market outperformance with 19% YoY growth during the quarter. \u27a2 North America formulations business growth was driven by sustained volume expansion and scale-up of specialty business. \u27a2 International Markets business sustained its growth trajectory with growth across markets supported by strong demand and focused execution. \u2751 Consumer Wellness delivered strong growth in India and sustained dominant market share in key brands; International business recorded a healthy like-to-like growth. \u2751 EBITDA margin stood at 24.0%. \u2751 Capex (organic) for the quarter: Rs. 4,655 mn. \u2751 Net Debt: Rs. 51,998 mn (as at 30-Sep\u201926) Q2 FY27: At a Glance Highlights of Q2 FY27 Rs. 79,096 mn 29% YoY Revenues from Operations Rs. 6,573 mn 8.3% of revenues R&D Rs. 18,945 mn 24.0% of revenues 6.0% YoY EBITDA & Margin % Rs. 9,255 mn 26.6% YoY Net Profit Business-wise Sales Break-up (Rs. mn) and YoY Growth 3 Regulatory Updates Total 77,544 \u25b228% Pharma (83%) \u25b218% \u25b222% \u25b221%\u25b230% \u25b233% \u25b247% \u25b276% 20,158 18,164 25,544 19,294 18,945 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 4,820 6,074 6,982 6,424 6,573 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 44,327 50,282 56,107 57,772 57,552 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Key Financial Metrics (1\/2) Total Revenues (Rs. mn) EBITDA (Rs. mn) and EBITDA Margin % Total R&D (Rs. mn) and % to Revenues Gross Profit (Rs. mn) and Gross Margin % 4 7.9 % 8.8% 9.2% 8.0% 8.3% 32.9% 26.5% 33.7% 24.1% 24.0% 72.4% 73.2% 72.1 % 72.8% 74.0% 61,232 68,645 75,870 80,170 79,096 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 72,513 75,938 81,987 86,143 83,052 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Key Financial Metrics (2\/2) Reported PAT (Rs. mn) 5 Net Debt to EBITDA (x) Organic Capex (Rs. mn) Net Working Capital* (Rs. mn) *Net working capital includes Inventory, Trade receivables and Trade payables. 12,609 10,484 13,185 9,604 9,255 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 4,911 4,637 3,577 5,875 4,655 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 0.28 0.34 0.49 0.68 0.62 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 15,926 17,094 17,528 18,158 18,844 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 India Formulations Sales (Rs. mn) Cardio-diabeto 18% Respi 13% Gynaec 5% Onco 10% Nephro 9% GI 9% Derma 5% Pain 7% AI 12% VMN 4% Others 8% 24% India Formulations business Outperformed IPM across super specialty, chronic and acute segments Highlights for the quarter *Source: AWACS MAT September 2026 data 18.3% Q2 FY27 Gr. YoY 3.8%QoQ Brand building - a key growth driver 1000+ 500 to 1000 250 to 500 # of Mother Brands Brand Value (Rs. Mn)* 20 29 28 Therapy-wise Break-up* Q2 FY27 Revenue Contribution \u25aa Branded business grew faster than the market with 19% YoY growth. \u25aa Consistently outperformed IPM growth over the last 3 financial years and during the first half of current fiscal. \u25aa Secondary sales growth was 20% y-o-y with volume and new products accounting for around two-third of the total growth. \u25aa Gained share in key therapies of Cardiology, Diabetology, Respiratory, Dermatology, Gastro- Intestinal, Anti-infectives and in super specialty areas of Oncology and Nephrology. \u25aa Ranking improved in key therapies of Cardiology, Diabetology, Gastro-Intestinal and Anti-infective therapies. \u25aa On the Super Specialty front, continued to retain leadership position in Oncology therapy. \u25aa Share of Chronic and sub-chronic portfolio has gone up consistently over the years and stood at 56.9%*, an improvement of 450 bps over the last 4 years. Growth drivers: \u2022 Chronic portfolio \u2022 Innovation and differentiated portfolio 27,437 28,043 29,523 30,979 33,145 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 North America Formulations Sales (Rs. mn) 516 455 Filings Approvals ANDA filings and approvals - Cumulative 9 22 Filings Approvals ANDA filings and approvals - H1 FY27 4 12 Filings Approvals ANDA filings and approvals - Q2 FY27 North America Formulations business Resilient performance on account of base business and branded portfolio Continued investment to build resilient product portfolio 7 20.8% Q2 FY27 Gr. YoY 7.0%QoQ Highlights for the quarter $ 313 mn $ 314 mn $ 323 mn Q2 FY27 Revenue Contribution $ 327 mn $ 347 mn US Generics \u25aa Base business continued to gain market share driven by sustained volume expansion and new launches. \u25aa Launched 5 new products during the quarter. \u25aa Launched the first generic version of Riociguat tablets in October 2026. \u25aa Filed 4 ANDAs and received approval for 12 ANDAs (incl. 2 tentative approvals). US Specialty \u25aa Delivered strong sequential growth, supported by Rolvedon\u00ae and continued momentum in the 505(b)(2) portfolio. ^ includes 2 tentative approvals in Q2 FY27, 7 in H1 FY27 and 31 on a cumulative basis. 43% Growth drivers: \u2022 Volume expansion \u2022 New launches \u2022 Branded and specialty portfolio ^ ^ ^ 7,513 7,881 8,041 9,735 10,009 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 IM Formulations Sales (Rs. mn) International Markets Formulations business Strong growth on the back of resilient demand across markets 8 33.2% Q2 FY27 Gr. YoY 2.8%QoQ Highlights for the quarter Q2 FY27 Revenue Contribution 13% \u25aa Growth was broad based in both Emerging markets (EM) and Europe driven by strong demand and focused execution. \u25aa In EM, adopted a focused, therapy led approach, tailoring the offerings to meet the needs of specific markets and in turn, built a more agile, market responsive portfolio. \u25aa In Europe, focus remains on broadening the portfolio and enhance the market coverage. Growth drivers: \u2022 Focused therapy approach in EM \u2022 Portfolio expansion and penetration in Europe \u2022 Focused execution 6,374 9,578 14,633 14,292 11,223 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Consumer Wellness Sales (Rs. mn) Consumer Wellness \u25aa Domestic business grew 29% y-o-y supported by sustained positive momentum across categories driven by steady urban recovery and improving rural demand. \u25aa Skin & hair care portfolio and food & nutrition portfolio registered 37% and 25% y-o-y growth respectively. \u25aa Organized channel saliency reached 38% (Modern Trade: 15% and E-commerce: 23%) in H1FY27. \u25aa International business, including CCL business, delivered 12% y-o-y growth on a like-to-like basis. 9 76.1% Q2 FY27 Gr. YoY -21.5%QoQ Strengthening presence across markets Key brands in India continued to hold dominant market share Brand Name Market Share# 60.0% 32.8% 96.0% 8.4% 50.2% 75.6% 3.9% , ## Mkt. Rank as per Company Estimates, #Source: Nielsen and IQVIA MAT Sep 2026 report, * Facial cleansing segment includes Face wash, Scrub and Peel -off Facial Cleansing * Scrub Peel Off Highlights for the quarter NA NA NA NA NA Fat spread Dairy Nutrition & Protein Bar Protein Cookies & Chips Other Nutrition Products Market Rank 1 1 1 4 1 1 4 1## NA 1 ## NA 1 ## Q2 FY27 Revenue Contribution 14% Growth drivers: \u2022 Product Innovation \u2022 Disciplined execution \u2022 Quick commerce\"},{\"title\":\"Change in Auditors\",\"summary\":\"Change in Auditors of the company.\",\"source\":\"NSE\",\"published\":\"04-Nov-2026 12:33:11\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_04112026123245_SEIntimationStatutoryAuditors.pdf\",\"disclosure_text\":\"November 4, 2026 BSE Limited Code: 532321 1st Floor, P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, 5th Floor, Plot No. C\/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Sub.: Intimation under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cthe Listing Regulations\u201d) Ref.: Appointment of statutory auditors pursuant to mandatory auditor rotation Dear Sir \/ Madam, Deloitte Haskins and Sells LLP (Firm Registration No. 117366W\/W-100018) (\u201c Deloitte\u201d), the existing statutory auditors, will complete its second term of 5 (five) consecutive years at the conclusion of 32 nd Annual General Meeting (\u201c AGM\u201d) for the financial year 2026-2027. Accordingly, Deloitte shall cease to hold office as the statutory auditors of the Company upon completion of its tenure, in accordance with the mandatory auditor rotation requirements prescribed under section 139(2) of the Companies Act, 2013. Based on the recommendation of the Audit Committee and subject to approval of the members of the Company, the Board of Directors at their meeting held on November 4, 2026, approved the appointment of M\/s. Walker Chandiok & Co LLP, Chartered Accountants, (Firm Registration No. 001076N\/N500013) (a member firm of Grant Thronton International) as the statutory auditors of the Company for the first term of 5 (five) years commencing from the conclusion of 32nd AGM for the financial year 2026-2027 and continuing until the conclusion of 37th AGM for the financial year 2031-2032. The resolution relating to appointment of M\/s. Walker Chandiok & Co LLP, Chartered Accountants, as the statutory auditors of the Company will be proposed to the members of the Company for approval at the 32nd AGM for financial year 2026-2027. Prescribed information as per the SEBI Master Circular dated January 30, 2026, are provided in Annexure-\u201cA\u201d. Please bring the aforesaid news to the notice of the members of the exchange and the investors\u2019 at large. The Board meeting commenced at 10:50 a.m. and concluded at 12:10 p.m. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Annexure-\u201cA\u201d Name M\/s. Walker Chandiok & Co LLP, Chartered Accountants, (Firm Registration No. 001076N\/N500013) (a member firm of Grant Thronton International) Reason for change viz. appointment Appointment of M\/s. Walker Chandiok & Co LLP, Chartered Accountants, as the statutory auditors of the Company consequent upon completion of the second consecutive term of 5 (five) years of Deloitte Haskins & Sells LLP, the existing statutory Auditors, at the conclusion of the 32 nd AGM of the Company for the financial year 2026-2027, in accordance with section 139(2) of the Companies Act, 2013. Effective date of appointment The appointment is from the conclusion of the 32 nd AGM of the Company for the financial year 2026-2027, subject to the approval of the members. Term of appointment First term of 5 (five) consecutive years, commencing from the conclusion of the 32 nd AGM of the Company for the financial year 2026-2027 and continuing until the conclusion of the 37th AGM of the Company for the financial year 2031-2032, subject to the approval of the members. Brief profile (in case of appointment) M\/s Walker Chandiok & Co LLP (Firm Registration no. 001076N\/N500013) is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India (ICAI) and is part of the Grant Thornton International network. The firm is over 90 years old and was established in the year 1935 with its registered office situated at New Delhi and having Nineteen other offices across major cities in India. It has ninety-nine partners. It has a valid peer review certificate. The firm is one of the India\u2019s leading audit firms providing audit and assurance services to several large companies including some of the top one hundred listed entities in India. The firm has significant experience in providing audit services to-leading pharmaceuticals and healthcare sectors and is supported by multidisciplinary teams comprising of audit, tax, technology and industry specialists. Disclosure of relationship between directors Not applicable\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Outcome of Board Meeting held on November 04, 2026.\",\"source\":\"NSE\",\"published\":\"04-Nov-2026 12:29:30\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_04112026122736_SEIntimationStatutoryAuditors.pdf\",\"disclosure_text\":\"November 4, 2026 BSE Limited Code: 532321 1st Floor, P J Towers, Dalal Street, Mumbai-400001 National Stock Exchange of India Limited Code: Zyduslife Exchange Plaza, 5th Floor, Plot No. C\/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051 Sub.: Intimation under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cthe Listing Regulations\u201d) Ref.: Appointment of statutory auditors pursuant to mandatory auditor rotation Dear Sir \/ Madam, Deloitte Haskins and Sells LLP (Firm Registration No. 117366W\/W-100018) (\u201c Deloitte\u201d), the existing statutory auditors, will complete its second term of 5 (five) consecutive years at the conclusion of 32 nd Annual General Meeting (\u201c AGM\u201d) for the financial year 2026-2027. Accordingly, Deloitte shall cease to hold office as the statutory auditors of the Company upon completion of its tenure, in accordance with the mandatory auditor rotation requirements prescribed under section 139(2) of the Companies Act, 2013. Based on the recommendation of the Audit Committee and subject to approval of the members of the Company, the Board of Directors at their meeting held on November 4, 2026, approved the appointment of M\/s. Walker Chandiok & Co LLP, Chartered Accountants, (Firm Registration No. 001076N\/N500013) (a member firm of Grant Thronton International) as the statutory auditors of the Company for the first term of 5 (five) years commencing from the conclusion of 32nd AGM for the financial year 2026-2027 and continuing until the conclusion of 37th AGM for the financial year 2031-2032. The resolution relating to appointment of M\/s. Walker Chandiok & Co LLP, Chartered Accountants, as the statutory auditors of the Company will be proposed to the members of the Company for approval at the 32nd AGM for financial year 2026-2027. Prescribed information as per the SEBI Master Circular dated January 30, 2026, are provided in Annexure-\u201cA\u201d. Please bring the aforesaid news to the notice of the members of the exchange and the investors\u2019 at large. The Board meeting commenced at 10:50 a.m. and concluded at 12:10 p.m. Thanking you, Yours faithfully, For, Zydus Lifesciences Limited Dhaval N. Soni Company Secretary and Compliance Officer Membership No. FCS7063 Encl.: As above Annexure-\u201cA\u201d Name M\/s. Walker Chandiok & Co LLP, Chartered Accountants, (Firm Registration No. 001076N\/N500013) (a member firm of Grant Thronton International) Reason for change viz. appointment Appointment of M\/s. Walker Chandiok & Co LLP, Chartered Accountants, as the statutory auditors of the Company consequent upon completion of the second consecutive term of 5 (five) years of Deloitte Haskins & Sells LLP, the existing statutory Auditors, at the conclusion of the 32 nd AGM of the Company for the financial year 2026-2027, in accordance with section 139(2) of the Companies Act, 2013. Effective date of appointment The appointment is from the conclusion of the 32 nd AGM of the Company for the financial year 2026-2027, subject to the approval of the members. Term of appointment First term of 5 (five) consecutive years, commencing from the conclusion of the 32 nd AGM of the Company for the financial year 2026-2027 and continuing until the conclusion of the 37th AGM of the Company for the financial year 2031-2032, subject to the approval of the members. Brief profile (in case of appointment) M\/s Walker Chandiok & Co LLP (Firm Registration no. 001076N\/N500013) is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India (ICAI) and is part of the Grant Thornton International network. The firm is over 90 years old and was established in the year 1935 with its registered office situated at New Delhi and having Nineteen other offices across major cities in India. It has ninety-nine partners. It has a valid peer review certificate. The firm is one of the India\u2019s leading audit firms providing audit and assurance services to several large companies including some of the top one hundred listed entities in India. The firm has significant experience in providing audit services to-leading pharmaceuticals and healthcare sectors and is supported by multidisciplinary teams comprising of audit, tax, technology and industry specialists. Disclosure of relationship between directors Not applicable\"}],\"recent_news\":[{\"summary\":\"Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"04-Nov-2026 12:19:04\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_04112026121711_OutcomeofBM.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Zydus Lifesciences Q1 Results Today: Time, Earnings Call, What To Watch, Share Price.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Zydus Life Q1 Result: Net Profit Falls 36% YoY Despite 22% Revenue Growth; Margin Contracts.\",\"category\":\"Business media\",\"published\":\"2026-08-11T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated October 21, 2026, titled \\\"Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production\\\".\",\"category\":\"Press Release\",\"date\":\"21-Oct-2026 18:27:15\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Cadilahc_21102026182006_PressRelease211020261.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"insider_activity\":[{\"person\":\"Jasodaben Babubhai Patel\",\"category\":\"Promoter Group\",\"type\":\"Buy\",\"quantity\":\"1000\",\"post_holding\":\"42577\",\"date\":\"12-Nov-2025\",\"mode\":\"Market Purchase\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":75.01,\"public_pct\":24.99,\"fii_pct\":7.05,\"dii_pct\":11.28,\"mf_pct\":6.88,\"institutional_pct\":18.33,\"noninst_pct\":6.66,\"mf_scheme_count\":41,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Parag Parikh Flexi Cap Fund\",\"shares\":20092313,\"pct\":2.01},{\"name\":\"Quant Mutual Fund - Quant Multi Cap Fund\",\"shares\":14847839,\"pct\":1.49},{\"name\":\"Kotak Flexicap Fund\",\"shares\":10684809,\"pct\":1.07}],\"period\":\"30-SEP-2026\",\"submission_date\":\"07-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1733872_07102026051035_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":75.01,\"previous_fii_pct\":6.88,\"previous_dii_pct\":11.27,\"previous_mf_pct\":5.12,\"previous_institutional_pct\":18.15,\"previous_mf_scheme_count\":38,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Kotak\",\"rating\":\"Buy\",\"target\":null,\"view_summary\":\"Five Stocks To Buy Today, November 02: Kotak Mahindra Bank, Zydus Lifesciences, Ather Energy, And More NDTV Profit\",\"headline\":\"Five Stocks To Buy Today, November 02: Kotak Mahindra Bank, Zydus Lifesciences, Ather Energy, And More\",\"published\":\"2026-11-02T02:05:53+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"Macquarie\",\"rating\":\"Outperform\",\"target\":null,\"view_summary\":\"Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating.\",\"headline\":\"Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why\",\"published\":\"2026-08-27T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"Citi\",\"rating\":\"Sell\",\"target\":null,\"view_summary\":\"Citi, Investec Raise Zydus Life Targets But Keep 'Sell'; Is The Stock Still Too Expensive?\",\"headline\":\"Citi, Investec Raise Zydus Life Targets But Keep 'Sell'; Is The Stock Still Too Expensive?\",\"published\":\"2026-08-12T07:00:00+00:00\",\"source\":\"NDTV Profit\"},{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Neutral\",\"target\":\"1125\",\"view_summary\":\"Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside \u2014 Check Revised Target Price\",\"headline\":\"Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside \u2014 Check Revised Target Price\",\"published\":\"2026-05-20T07:00:00+00:00\",\"source\":\"NDTV Profit\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences share price fell 4.23% to \u20b91,188.10 today. See why ZYDUSLIFE is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":10745,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Zydus Lifesciences Share Price Today: Why ZYDUSLIFE Is Falling 4.23% | 4 November 2026","_witty_meta_description":"Zydus Lifesciences share price fell 4.23% to \u20b91,188.10 today. See why ZYDUSLIFE is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Zydus Lifesciences share price today","_witty_reason_label":"profit-taking following earnings and regulatory updates","_witty_reason_confidence":"high","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[122],"class_list":["post-10746","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-zyduslife"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=10746"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10746\/revisions"}],"predecessor-version":[{"id":10747,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10746\/revisions\/10747"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/10745"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=10746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=10746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=10746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}